Shares of G1 Therapeutics GTHX rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 28.72% year over year to ($0.67), which beat the estimate of ($0.87).
Revenue of $16,546,000 up by 0.00% from the same period last year, which beat the estimate of $4,060,000.
Looking Ahead
G1 Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Feb 24, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/n2his4rc
Price Action
Company's 52-week high was at $37.07
Company's 52-week low was at $8.80
Price action over last quarter: Up 116.89%
Company Profile
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer such as cell lung cancer and breast cancer and designs them to combine - and enhance - the anti-tumor activity of current therapies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
